AI-enabled solutions for
drug discovery
We combine human and artificial intelligence to accelerate drug discovery.
Built from decades of proprietary experimental data and decades of expertise in early drug discovery, our expert systems platform informs decision making and enables the selection of candidate drugs for clinical trials and research.
Taking drug discovery to the next level.
Our comprehensive suite of AI models covers all aspects of preclinical drug discovery, from target identification and selection and virtual screening, to pharmacokinetics and off target pharmacology, including chemical liability assessment and in vitro toxicology. Using proprietary and public databases and software, we evaluate the intellectual property landscape and provide competitive intelligence to de-risk candidate selection for fast transition from in silico to first-time-in-man.
Discover Medicines Hybrid AI Platform
-
System for searching for prospective biotargets.
-
Knowledge base and KGML models for target phenotype relationships
-
A suite of LLM- based tools to access biomedical data, databases, and ML models
-
SMILES based ML models for bioactivity and ADMET property prediction
Team of drug discovery innovators.
Our team consists of early drug discovery experts, the brightest academic minds and seasoned life science investors, as well as AI and machine learning innovators with extensive knowledge and decades of proprietary experimental data.